New HIV tablet for people who haven't had treatment
Part of Immune system & allergy, Infections clinical trials.
This trial is testing a new oral tablet called ACC017 for people living with HIV who have never taken HIV medication before. It aims to see if the drug is safe and can help lower the amount of virus in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have HIV-1 and never have taken any HIV medication or vaccine.
- Your viral load (amount of HIV in your blood) must be at least 5000 copies/mL.
- Your CD4 count (an immune cell) must be above 200.
- You must not be pregnant, breastfeeding, or planning pregnancy during the study.
- You must be willing to avoid certain foods, drinks, and other medications for a short time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
This trial tests a new injectable treatment called LP-98 for people with HIV who have never taken HIV medications before. It aims to see if the drug is safe and can help lower the virus in your body.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Hear when a new Infection, Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.